Insulin Resistance in the UK: NICE Guidelines Explained

TL;DR

"Insulin resistance UK NICE guidelines" usually refers to how NICE and NHS recommend identifying and managing people at high risk of type 2 diabetes (non‑diabetic hyperglycaemia). The key UK thresholds are HbA1c 42–47 mmol/mol or fasting plasma glucose 5.5–6.9 mmol/L; NICE PH38 endorses a two‑stage risk assessment and referral to quality‑assured lifestyle programmes, with metformin orlistat considered for specific groups. Use NHS Diabetes Prevention Programme resources and follow-up annually. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))

What is insulin resistance?

Insulin resistance is a metabolic state in which insulin — the hormone that helps cells take up glucose — becomes less effective. The pancreas compensates by producing more insulin; over time this may lead to elevated blood glucose and eventually to prediabetes and type 2 diabetes if beta‑cell function declines. Insulin resistance is central to the development of type 2 diabetes and is associated with obesity, physical inactivity, some medications, polycystic ovary syndrome (PCOS), and ageing. ([nature.com](https://www.nature.com/articles/s41580-021-00390-6))

How NICE frames insulin resistance and 'high risk' of type 2 diabetes

NICE (the National Institute for Health and Care Excellence) does not publish a standalone guideline titled "insulin resistance". Instead, the public‑health guidance "Type 2 diabetes: prevention in people at high risk" (PH38) deals with identifying people at high risk of type 2 diabetes — the clinical group in which insulin resistance is commonly present. NICE uses the term "non‑diabetic hyperglycaemia" (NDH) or "high risk of type 2 diabetes" to describe raised blood glucose that is not yet in the diabetic range and provides practical steps for primary care services. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))

Screening & diagnosis in the UK (mmol/L and mmol/mol)

NICE PH38 recommends a two‑stage identification strategy: an initial risk assessment (questionnaire or risk tool) followed, when indicated, by a blood test (HbA1c or fasting plasma glucose). NDH thresholds used across NHS and NICE are:

• HbA1c 42–47 mmol/mol (6.0–6.4%) = non‑diabetic hyperglycaemia (NDH). ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
• HbA1c ≥48 mmol/mol (6.5%) — diagnostic for diabetes (confirm with a second test in asymptomatic patients). ([diabetes.org.uk](https://www.diabetes.org.uk/for-professionals/improving-care/clinical-recommendations-for-professionals/diagnosis-ongoing-management-monitoring/new_diagnostic_criteria_for_diabetes))
• Fasting plasma glucose 5.5–6.9 mmol/L = NDH; ≥7.0 mmol/L is suggestive of diabetes. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))

Note: routine primary‑care practice in the UK generally uses HbA1c for convenience because the test does not require fasting; local services may use fasting glucose when HbA1c is unreliable (e.g., haemoglobinopathies). Annual monitoring is advised for people with NDH. ([healthcheck.nhs.uk](https://www.healthcheck.nhs.uk/seecmsfile/?id=1381))

Who is at higher risk in the UK — inequalities & population groups

In the UK, NDH and insulin resistance are more prevalent in people with overweight or obesity, older adults, people with a family history of type 2 diabetes, and those from Black, African, Caribbean and South Asian ethnic groups. Deprived communities are disproportionately affected, and regional variation exists across England, Scotland, Wales and Northern Ireland. Diabetes UK and NHS data estimate millions living with NDH or diabetes in the UK and highlight inequalities in access and outcomes. ([diabetes.org.uk](https://www.diabetes.org.uk/sites/default/files/2026-01/GDM%20NDH%20Position%20Statement%20V5%20Final.pdf))

What the NICE guidance recommends (practical summary)

1. Two‑stage identification: use a validated risk tool (for example Diabetes UK "Know Your Risk") and follow with blood testing (HbA1c or fasting glucose) where indicated. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
2. Structured lifestyle referral: people with NDH should be offered referral to a quality‑assured intensive lifestyle change programme (aiming for weight loss, increased physical activity and healthier diet). The NHS Diabetes Prevention Programme (DPP) is the national example. ([digital.nhs.uk](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit-ndh-dpp/dpp-e3-25-26/non-diabetic-hyperglycaemia))
3. Monitoring: at least annual review of HbA1c or FPG, weight/BMI and lifestyle factors. ([healthcheck.nhs.uk](https://www.healthcheck.nhs.uk/seecmsfile/?id=1381))
4. Pharmacology: metformin should be considered in selected people where lifestyle intervention is not possible or if glucose deteriorates despite lifestyle measures (clinical judgement required); orlistat may be considered in some patients with high BMI. These are not routine for everyone with NDH. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
5. Addressing inequalities: active approaches to identify at‑risk people in deprived and minority communities are recommended. ([diabetes.org.uk](https://www.diabetes.org.uk/sites/default/files/2026-01/GDM%20NDH%20Position%20Statement%20V5%20Final.pdf))

NHS Diabetes Prevention Programme & local services

The NHS DPP (often called "Healthier You") is a national, evidence‑based behavioural programme delivered locally to help people with NDH reduce their risk of developing type 2 diabetes. GPs and primary‑care teams should refer eligible patients; the programme focuses on weight loss, dietary change and increased activity. Audit and monitoring data from NHS Digital show DPP implementation across England; local availability and referral criteria can vary by Integrated Care Board (ICB). ([digital.nhs.uk](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit-ndh-dpp/dpp-e3-25-26/non-diabetic-hyperglycaemia))

Managing insulin resistance in primary care: lifestyle, drugs and specialist options

First‑line: lifestyle changes aimed at weight loss (even modest loss of 5–10% body weight produces meaningful metabolic benefit), increased physical activity (150 minutes/week of moderate activity as a minimum), improved diet quality (more wholegrains, fibre, vegetables, less saturated fat and refined carbs). NICE PH38 and NHS materials emphasise structured programmes rather than advice alone. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))

Drug options:

• Metformin — may be offered when lifestyle change is insufficient or impractical, particularly for people at very high risk (e.g., BMI ≥35 kg/m2) or with progressive hyperglycaemia. NICE discusses selective use rather than universal prescription. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
• Orlistat — NICE suggests consideration for weight loss in patients meeting BMI criteria. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))

Specialist care: for people with severe insulin resistance, genetics or complicated metabolic disease, tertiary services exist — for example the UK National Severe Insulin Resistance Service at Cambridge University Hospitals. These services assess rare causes of extreme insulin resistance and coordinate specialist management. ([cuh.nhs.uk](https://www.cuh.nhs.uk/our-services/diabetes/national-severe-insulin-resistance-service/))

Evidence for remission and weight‑loss approaches

High‑quality UK research shows that substantial weight loss — often achieved with total diet replacement programmes or intensive support — can normalise blood glucose and induce remission of type 2 diabetes in many people, especially when diabetes duration is short. The BMJ and other academic reviews highlight the physiological mechanisms (reduced liver and pancreatic fat, restored beta‑cell function) that underpin remission. These findings reinforce NICE and NHS emphasis on early identification and structured weight‑loss interventions. ([bmj.com](https://www.bmj.com/content/374/bmj.n1449))

Advanced and emerging interventions (what NICE says)

NICE also evaluates newer technologies and procedures. For example, evidence reviews and guidance cover interventional approaches such as endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (HealthTech Guidance HTG721) — these are specialist procedures and not standard first‑line care. NICE's role is to appraise safety and effectiveness before routine NHS adoption. ([nice.org.uk](https://www.nice.org.uk/guidance/htg721))

Practical tips for patients and clinicians in the UK

• Ask your GP for a risk assessment (Diabetes UK "Know Your Risk" is widely used) if you are overweight, have a family history, are from a high‑risk ethnic group, or have had gestational diabetes. ([diabetes.org.uk](https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/hba1c))
• If offered an HbA1c, remember UK units: results are reported in mmol/mol (not %). Aim to keep HbA1c below 42 mmol/mol if you're at risk. ([diabetes.org.uk](https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/hba1c))
• Referral to the NHS Diabetes Prevention Programme should be discussed for NDH; check your local ICB for availability and waiting lists. ([digital.nhs.uk](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit-ndh-dpp/dpp-e3-25-26/non-diabetic-hyperglycaemia))
• Medication like metformin may be an option when lifestyle changes are not sufficient — this is a shared decision with your GP and depends on individual risk. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
• Cardiovascular risk assessment and management are important: insulin resistance increases the risk of heart and circulatory disease, so blood pressure, lipids and smoking status should be addressed. The British Heart Foundation has patient resources on this link. ([bhf.org.uk](https://www.bhf.org.uk/informationsupport/risk-factors/diabetes))

FAQ

Scientific references & further reading

1. NICE. Type 2 diabetes: prevention in people at high risk (PH38) — recommendations and indicators. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))
2. NICE. HealthTech guidance HTG721 — Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. ([nice.org.uk](https://www.nice.org.uk/guidance/htg721))
3. Diabetes UK. Insulin resistance: meaning, causes & treatment; and resources on prediabetes/NDH. ([diabetes.org.uk](https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/insulin/resistance))
4. NHS. Information on pre‑diabetes (non‑diabetic hyperglycaemia), Diabetes Prevention Programme and diabetes patient resources. ([nhs.uk](https://www.nhs.uk/conditions/diabetes/))
5. British Heart Foundation. Diabetes and cardiovascular disease — links and research summaries. ([bhf.org.uk](https://www.bhf.org.uk/informationsupport/risk-factors/diabetes))
6. BMJ. Reviews on nutritional basis of type 2 diabetes remission and weight‑loss evidence (Taylor et al.). ([bmj.com](https://www.bmj.com/content/374/bmj.n1449))
7. Nature Reviews (or comparable high‑impact reviews) on the molecular aetiology of insulin resistance. ([nature.com](https://www.nature.com/articles/s41580-021-00390-6))
8. Cambridge University Hospitals. National Severe Insulin Resistance Service (clinical service description). ([cuh.nhs.uk](https://www.cuh.nhs.uk/our-services/diabetes/national-severe-insulin-resistance-service/))
9. NHS Digital & Public Health reports on the Diabetes Prevention Programme and NDH audit reports. ([digital.nhs.uk](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit-ndh-dpp/dpp-e3-25-26/non-diabetic-hyperglycaemia))

Medical disclaimer

This article provides general information about insulin resistance and how NICE and NHS guidance apply in the UK. It does not replace individual clinical assessment. For personalised medical advice, diagnosis, or treatment, consult your GP, diabetes specialist nurse or another qualified health professional at your local NHS service. If you are experiencing symptoms you believe to be urgent (very high blood glucose, extreme thirst, vomiting, breathlessness, rapid heartbeat or confusion), seek immediate medical attention or call 111 / 999 as appropriate. The references cited are current at the time of writing; check NICE, NHS and Diabetes UK websites for the latest updates. ([nice.org.uk](https://www.nice.org.uk/guidance/ph38/chapter/recommendations))